{"name":"Hanny Al-Samkari, MD","slug":"hanny-al-samkari-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bevacizumab (Avastin®)","genericName":"Bevacizumab (Avastin®)","slug":"bevacizumab-avastin","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"marketed"}]}],"pipeline":[{"name":"Bevacizumab (Avastin®)","genericName":"Bevacizumab (Avastin®)","slug":"bevacizumab-avastin","phase":"marketed","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Metastatic non-small cell lung cancer (in combination with chemotherapy)","Metastatic breast cancer (in combination with paclitaxel)","Glioblastoma (recurrent)","Metastatic renal cell carcinoma (in combination with interferon-alpha)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxObzJRSXAtazdRM29ZOTdNSjJTSHRlOHdST0tOakFtUE1rcXZoUjQyWlNTenA2Tml4cWt2NHNCNjN4X2N0X3hvOUNMWEZNQUxwMktzdDJjQThqZzZ6UExNTlc0XzRFR1FxX21HdkZWaWs0Q2dJTHAxYV9oVUZ1QWlSVmF4MnUxcHRrRHQxUUo2cw?oc=5","date":"2026-03-12","type":"trial","source":"Medical Xpress","summary":"Romiplostim prevents serious side effect of chemotherapy in phase 3 trial - Medical Xpress","headline":"Romiplostim prevents serious side effect of chemotherapy in phase 3 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9WOVpScXBzdGlDNHpMalpkUFhPcWdjVXgxRENLSHNILTJaYy1va0d2OXYxVUhNMVdFV3h2eUlWQ3U3TlRUZmVRR2Y0RDlDMzExdXd0a0dRS0szU01aWXd5a0RsNTBrSFlSVHd5V2l2SThpSFk?oc=5","date":"2026-03-11","type":"pipeline","source":"MedPage Today","summary":"Drug Cuts Treatment Modifications From Chemotherapy-Induced Thrombocytopenia - MedPage Today","headline":"Drug Cuts Treatment Modifications From Chemotherapy-Induced Thrombocytopenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPdEhUWEpvRVpMNHZyYVZBZFpVY0FCMEY0ZGZZOUFKSkV6QnRvUzJTMGhNeEZfSnBGellUWWQ4SXo0Wk53a2p5WUhLNTlzWkhiZ2tUVFVlWU9PcDJ3OFlqczZjU3BpaU1Sb3JkXzhWbG5kY29kWDlHbXlQQXRKWjFmRl9LOTNlMk9pS3Y2Vlg3bnBiX2FRVDk5QXJUbmoyT25hWVE1SzN3OUU1VGNWYS04YTNXb3V0Qlk?oc=5","date":"2025-12-19","type":"pipeline","source":"HCPLive","summary":"Systemic Bevacizumab Improves Chronic Bleeding from GI Lesions, With Hanny Al-Samkari, MD - HCPLive","headline":"Systemic Bevacizumab Improves Chronic Bleeding from GI Lesions, With Hanny Al-Samkari, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOYjJ2UnItQkJQcGhDUGlDNEtBSjI1a2hiYUNXYWJTc0c4YjY0RzF0cUk4YTlkS1djandncGtKQ3UzQm5wTl9rbjFJcHBQQVNiUERkV05FM0p1aUI0RFQ3dUdIWlh3RVJUUGE3MldQV2dXMFZ3elRuczRoMXNLRkRMMzd5LVRnT1lmbkdNXzlEaGxfVnliazM2RmdyTDBRSjJzbmZoOHNfNzBCYXFuYlJpSUxmOEVqYlpoYjl0QmVrLXZqWGtFUTVwcG5n?oc=5","date":"2025-12-18","type":"pipeline","source":"HCPLive","summary":"Patients with HHT Exhibit More Severe Complications Than Previously Believed, With Hanny Al-Samkari, MD - HCPLive","headline":"Patients with HHT Exhibit More Severe Complications Than Previously Believed, With Hanny Al-Samkari, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPaHNaM0kzZ1E0RU9BYU1oc2ViOFpZT3FKOFVIZUlSQXpfQm5XVXB2NTdoLXJ5aTJlalo5MXk4V3F5d2tSYUNUdXE1a1pNX0xfMk5Kc3ZibVZZbUNwZVp0V3hoTTRzWU5peVBFaDcyaXBTdE9vZzl2Wk9CTzNOc3J4ZWJyTExqLWdkOFlpTFc5dmpEX2hoQUFyTjJ3d3hHR0JnVjBHOVNR?oc=5","date":"2025-12-12","type":"pipeline","source":"Medscape","summary":"Ianalumab Prolongs Time to Treatment Failure in Primary ITP - Medscape","headline":"Ianalumab Prolongs Time to Treatment Failure in Primary ITP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE56LXRSVkVjc2xZXzVEam5LWXkyMEt3Y0Z5bGFSY3JuaEJjVEhzVk9JUEV0WUVVR2ZnQ2loRWFXSzdjbVppa3pFSERTOC01SWRZNy1Pb1hFSFB1dw?oc=5","date":"2025-12-09","type":"pipeline","source":"NEJM","summary":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia - NEJM","headline":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOQjJFdk5UV2RIUG5ZNU1EWUhaQ2V4c2l3Q3VGdWx6aE5MRkthUlBRbUtVSzNzaFlDT0tpNVdYYmhtUjVOMlVPbnExaldfQ1BlMmdDSzh3RGhfei1VN0pweGozRTd0cnZpV3hEUGVJRFBxVE9ya1drajZaVFRBeVVySDBNbWxUbVBPN2Rka2pkTHlPT2ZBN1I4bzJRa3k1ODY2bHNhbFY3cU5KZll1MVI0aDM3VWtoWFVVUHJ2Y0xJSFdGc2ZNSktBSV9LZ2FZNUEtSDNKT0Z3?oc=5","date":"2025-12-09","type":"pipeline","source":"Healio","summary":"Ianalumab regimen may provide ‘true disease modification’ in immune thrombocytopenia - Healio","headline":"Ianalumab regimen may provide ‘true disease modification’ in immune thrombocytopenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPdE1xdDN2LTgxRkxEU3VWakJReUt1SDdHbzZVNFExWjRESTNUYzRtSkpZS09tdnVvMk5idzlnTlV4amt1ckkycVBlRGtZSGM5SV9BalRwZWlHOHRBSktHYkVBTzFvaWc1M085Q01rZEMzRDVsUHhfNEhqNDVNXzZxSGNNUkZCVy1kcGdBb3A0UTVKdWlPeWpZdHk2YUYzZzBrc2c?oc=5","date":"2025-12-09","type":"trial","source":"Fierce Biotech","summary":"ASH: Novartis details ianalumab's phase 3 rare blood disease win - Fierce Biotech","headline":"ASH: Novartis details ianalumab's phase 3 rare blood disease win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNVlRiaXJBay1ENFExV3VlTDhxcmh3NENLakl4eFFidnUyV05zdVZXN2ZZeEl6Uy1NdVZJNExDc3hKLWtvSFVhRnpEcmhTNUhYTmhUNUxfOUVMMDJIaU9BcHAzWTVCYVEyUzlFdERkUUZSek5QUVdQZUlBUEYtMmlmNTRiZFVjWGJmMFlCM0NOUGF2WW4ya1lhQ3hkcExGUmFIcHlEWFpzdGZIcG1tMmhnQnpNbzNNaVBfUG5udldaZU4yR1RQdC1nSHpibFZFNmZtQmNrdGRzc0FrSHVoamNzV1hPOVJiSU1Wb0tNMnJrVFVQbVFucWxn?oc=5","date":"2025-12-09","type":"pipeline","source":"NEJM","summary":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia - NEJM","headline":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"BioSpace","summary":"Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Heredit","headline":"Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5UdmE4R0ZJNGhKdEpubHg2Rzc5Ui0zYlFGeXBnOVZlQkF3U0VNVXZVV0NQWGdJeGNZeG52T1lXUVlOaFhDaF9xUDM0YVdjMjFOcmNXdHNwUlA3QUFiV0ZWWlctUQ?oc=5","date":"2025-07-02","type":"pipeline","source":"Wiley Online Library","summary":"Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia - Wiley Online Library","headline":"Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOR2ZGZE1HemxkZUREeGdiSmV2MmJ5OU5NMXBsNW92bnV5bUIyUlhHNzVxN3F4TmhidjVkRkZLMDlqaldmU3VxZU5RU2xlbTl4RlUtejRhMUNkbURnUWc4NE1EcFBKLUtudmJxclFVUXp4b3paZ2czY0FfX0VpOFNrTTB3RXV1X0ZvcHVDR0FSZ1BOVzg1SFpRRVN4dW1MOFNTQXk0OEJWOVVMM00zVlJBYQ?oc=5","date":"2025-06-03","type":"pipeline","source":"Oncology News Central","summary":"Romiplostim Effective for Chemotherapy-induced Thrombocytopenia in Gastrointestinal Cancers - Oncology News Central","headline":"Romiplostim Effective for Chemotherapy-induced Thrombocytopenia in Gastrointestinal Cancers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}